Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP13447.RAtfEut3KlzH_j7lQ59xvHF732sWh-PTnlyEeQ7829DPI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP13447.RAtfEut3KlzH_j7lQ59xvHF732sWh-PTnlyEeQ7829DPI130_assertion type Assertion NP13447.RAtfEut3KlzH_j7lQ59xvHF732sWh-PTnlyEeQ7829DPI130_head.
- NP13447.RAtfEut3KlzH_j7lQ59xvHF732sWh-PTnlyEeQ7829DPI130_assertion wasGeneratedBy ECO_0000218 NP13447.RAtfEut3KlzH_j7lQ59xvHF732sWh-PTnlyEeQ7829DPI130_provenance.
- NP13447.RAtfEut3KlzH_j7lQ59xvHF732sWh-PTnlyEeQ7829DPI130_assertion wasDerivedFrom ctd_human-20130708 NP13447.RAtfEut3KlzH_j7lQ59xvHF732sWh-PTnlyEeQ7829DPI130_provenance.
- NP13447.RAtfEut3KlzH_j7lQ59xvHF732sWh-PTnlyEeQ7829DPI130_assertion SIO_000772 15248218 NP13447.RAtfEut3KlzH_j7lQ59xvHF732sWh-PTnlyEeQ7829DPI130_provenance.
- NP13447.RAtfEut3KlzH_j7lQ59xvHF732sWh-PTnlyEeQ7829DPI130_assertion evidence source_evidence_curated NP13447.RAtfEut3KlzH_j7lQ59xvHF732sWh-PTnlyEeQ7829DPI130_provenance.
- NP13447.RAtfEut3KlzH_j7lQ59xvHF732sWh-PTnlyEeQ7829DPI130_assertion description "[Patients who were either heterozygous or homozygous for CYP2C19*2 had a significantly lower risk of developing premature ovarian failure (relative risk 0.10; 95% confidence interval 0.02-0.52), after adjustment for age and total number of cyclophosphamide pulses received.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP13447.RAtfEut3KlzH_j7lQ59xvHF732sWh-PTnlyEeQ7829DPI130_provenance.